Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC raised its holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Rating) by 27.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The firm owned 7,045 shares of the company’s stock after acquiring an additional 1,526 shares during the quarter. Allspring Global Investments Holdings LLC’s holdings in Ionis Pharmaceuticals were worth $311,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Wipfli Financial Advisors LLC acquired a new stake in Ionis Pharmaceuticals in the third quarter valued at $27,000. Ronald Blue Trust Inc. acquired a new stake in Ionis Pharmaceuticals in the second quarter valued at $25,000. Heritage Wealth Management LLC acquired a new stake in Ionis Pharmaceuticals in the second quarter valued at $25,000. Heritage Financial Services LLC acquired a new stake in Ionis Pharmaceuticals in the second quarter valued at $33,000. Finally, Quantbot Technologies LP acquired a new stake in Ionis Pharmaceuticals in the second quarter valued at $44,000. Institutional investors and hedge funds own 87.32% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on IONS shares. Morgan Stanley downgraded Ionis Pharmaceuticals from an “overweight” rating to an “equal weight” rating and reduced their target price for the company from $56.00 to $40.00 in a report on Wednesday, December 21st. SVB Leerink raised their price target on Ionis Pharmaceuticals from $32.00 to $33.00 and gave the company a “market perform” rating in a research report on Monday. Citigroup raised their price target on Ionis Pharmaceuticals from $28.00 to $31.00 and gave the company a “sell” rating in a research report on Thursday, November 10th. StockNews.com started coverage on Ionis Pharmaceuticals in a research report on Wednesday, October 12th. They issued a “hold” rating for the company. Finally, Piper Sandler raised their price target on Ionis Pharmaceuticals from $60.00 to $62.00 and gave the company an “overweight” rating in a research report on Thursday, January 19th. Two equities research analysts have rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. According to MarketBeat, Ionis Pharmaceuticals presently has an average rating of “Hold” and an average target price of $44.00.

Insider Buying and Selling at Ionis Pharmaceuticals

In other Ionis Pharmaceuticals news, Director Joseph Klein III sold 2,000 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, January 17th. The stock was sold at an average price of $40.00, for a total value of $80,000.00. Following the completion of the sale, the director now owns 16,791 shares in the company, valued at approximately $671,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. In other news, CEO Brett P. Monia sold 25,066 shares of Ionis Pharmaceuticals stock in a transaction dated Wednesday, January 18th. The stock was sold at an average price of $39.49, for a total value of $989,856.34. Following the transaction, the chief executive officer now directly owns 120,863 shares of the company’s stock, valued at approximately $4,772,879.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph Klein III sold 2,000 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, January 17th. The shares were sold at an average price of $40.00, for a total value of $80,000.00. Following the completion of the transaction, the director now directly owns 16,791 shares in the company, valued at $671,640. The disclosure for this sale can be found here. Insiders sold 40,977 shares of company stock worth $1,622,348 in the last 90 days. 2.36% of the stock is owned by company insiders.

Ionis Pharmaceuticals Trading Up 1.6 %

Ionis Pharmaceuticals stock opened at $40.07 on Wednesday. The stock has a market cap of $5.69 billion, a PE ratio of -333.89 and a beta of 0.54. The stock has a 50-day moving average price of $39.37 and a 200 day moving average price of $41.90. Ionis Pharmaceuticals, Inc. has a 52 week low of $28.25 and a 52 week high of $48.82. The company has a current ratio of 7.59, a quick ratio of 7.52 and a debt-to-equity ratio of 2.10.

Ionis Pharmaceuticals (NASDAQ:IONSGet Rating) last posted its quarterly earnings data on Wednesday, November 9th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.41. The firm had revenue of $160.00 million during the quarter, compared to analysts’ expectations of $149.48 million. Ionis Pharmaceuticals had a return on equity of 1.18% and a net margin of 0.91%. Equities research analysts predict that Ionis Pharmaceuticals, Inc. will post -2.49 earnings per share for the current fiscal year.

Ionis Pharmaceuticals Company Profile

(Get Rating)

Ionis Pharmaceuticals, Inc engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases.

Further Reading

Want to see what other hedge funds are holding IONS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ionis Pharmaceuticals, Inc. (NASDAQ:IONSGet Rating).

Institutional Ownership by Quarter for Ionis Pharmaceuticals (NASDAQ:IONS)

Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.